Bio-Rad Laboratories (BIO) Non-Current Deferred Tax Liability (2009 - 2026)

Bio-Rad Laboratories (BIO) has reported Non-Current Deferred Tax Liability for 18 consecutive years, with $982.2 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Non-Current Deferred Tax Liability rose 2.21% year-over-year to $982.2 million in Q2 2026; TTM through Jun 2026 was $982.2 million, a 2.21% increase from a year earlier, with the FY2025 full-year figure at $1.1 billion, up 14.26% from the prior year.
• Non-Current Deferred Tax Liability was $982.2 million for Q2 2026 at Bio-Rad Laboratories, up from $881.8 million in the prior quarter.
• Over five years, Non-Current Deferred Tax Liability peaked at $2.0 billion in Q1 2022 and troughed at $840.8 million in Q1 2025.
• A 5-year average of $1.3 billion and a median of $1.2 billion in 2023 frame the typical range for Non-Current Deferred Tax Liability.
• Across the five-year window, Non-Current Deferred Tax Liability sank 58.41% in 2022 and gained 14.26% in 2025, its largest moves.
• Over 5 years, Non-Current Deferred Tax Liability stood at $1.9 billion in 2022, then fell by 14.43% to $1.6 billion in 2023, then slumped by 43.59% to $927.2 million in 2024, then grew by 14.26% to $1.1 billion in 2025, then slipped by 7.29% to $982.2 million in 2026.
• The last three Non-Current Deferred Tax Liability figures came in at $982.2 million (Q2 2026), $881.8 million (Q1 2026), and $1.1 billion (Q4 2025), per Business Quant data.